Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Quantum-Si, Element Biosciences, Synthego, NeoGenomics, More

Quantum-Si: Jonathan Rothberg

Quantum-Si has appointed Jonathan Rothberg as interim CEO. Rothberg, Quantum-Si's founder and executive chairman, replaced former CEO John Stark on Feb. 8. The firm has begun a search to identify a permanent CEO.

Element Biosciences: Shawn Levy

Shawn Levy has joined sequencing technology company Element Biosciences as senior VP of applications and scientific affairs. He comes to Element from Discovery Life Sciences, where he was CSO. Before that, he headed the genomics services laboratory at the HudsonAlpha Institute for Biotechnology, where he remains a faculty investigator. Levy holds a Ph.D. in biochemistry from Emory University School of Medicine.

Synthego: Avi Raval

Avi Raval has been appointed as CFO of gene editing company Synthego. Previously, he was a managing director and founding member of the healthcare group at Perella Weinberg Partners, where he also served as chief operating officer of the firm's advisory business. Before that, he was at JP Morgan. Raval holds a B.A. from the University of Pennsylvania and an MBA from the university's Wharton School.

NeoGenomics: Shashikant Kulkarni

Shashikant Kulkarni will join NeoGenomics as executive VP for research and development and CSO on March 7. Most recently, he served as CSO and senior VP of innovation and emerging business at Baylor Genetics, and as a tenured professor and vice chairman for research in the department of molecular and human genetics at Baylor College of Medicine. Previously, he was head of clinical genomics and a professor of pathology and immunology at Washington University School of Medicine in St. Louis. Kulkarni has also served as an expert panelist with several regulatory agencies, including the US Food and Drug Administration, the US Centers for Disease Control and Prevention, the Centers for Medicare and Medicaid Services, and the National Institutes of Health. In addition, he is the editor-in-chief of Cancer Genetics.

For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.